PERSONALIZED STATIN THERAPY IN IMPROVING THE TREATMENT OF CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS-Reference-Cited by-同舟云学术

PERSONALIZED STATIN THERAPY IN IMPROVING THE TREATMENT OF CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS

Published:2015-06-30 Issue:2 Volume: Page:57-61
ISSN:2305-0748
Container-title:Eurasian heart journal
language:
Short-container-title:Evrazijskij kardiologičeskij žurnal

Author:

Makhmudova U. R.¹,Hoshimov Sh. U.²,Abdullayeva G. J.²,Shek A. B.²,Kurbanov R. D.²

Affiliation:

1. Tashkent Medical Academy

2. Republican Specialized Center of Cardiology

Abstract

This review examines the possibility of personalized pharmacotherapy with statins, based on the genotype of the individual patient. Identification of polymorphism of genes, responsible for the metabolism of the liver CYP3A5, CYP2C9 and transport of statins into the liver SLCO1B1, BCRP allows differentiated approach to their appointment and choice. This will not only increase the effectiveness of statins, but also to avoid serious side effects, primarily statin-induced myopathy and toxic hepatitis.

Publisher

Intermedservice Ltd

Subject

General Medicine

Reference33 articles.

1. Karjinami K., Takekoshi N., et al. Pharmacogenetics of HMG-CoA reductase inhibitors; exploring the potential for genotype-based indivualization of coronary diseasemanagement. Atherosklerosis 2004, 177(2). 219-234.

2. Bochkov P.G. Geneticheskie podkhody k otsenke bezopasnosti i effektivnosti lekarstvennykh sredstv. Klinicheskie issledovaniya lekarstvennykh sredstv v Rossii 2002; 2: 4-6.

3. Kukes V.G. Klinicheskaya farmakologiya. Moskva «GEOTARMED» 2004;154- 168.

4. Seredenin S.B. Lektsii po farmakogenetike. Moskva «MIA» 2004; 303 s.

5. Gonzalez F.J., Mackenzie P.I., Kimura S. Et al. Isolation and characterization of mouse full-length cDNA and genomic clones of 3-methylcholantherene-inducible cytochrome P1-450 and P3-450. Gene 1984. 29.281-292.